188 related articles for article (PubMed ID: 38177459)
1. Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping.
Warner EW; Van der Eecken K; Murtha AJ; Kwan EM; Herberts C; Sipola J; Ng SWS; Chen XE; Fonseca NM; Ritch E; Schönlau E; Bernales CQ; Donnellan G; Munzur AD; Parekh K; Beja K; Wong A; Verbeke S; Lumen N; Van Dorpe J; De Laere B; Annala M; Vandekerkhove G; Ost P; Wyatt AW
Nat Cancer; 2024 Jan; 5(1):114-130. PubMed ID: 38177459
[TBL] [Abstract][Full Text] [Related]
2. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
[TBL] [Abstract][Full Text] [Related]
3. Percutaneous image-guided biopsy of prostate cancer metastases yields samples suitable for genomics and personalised oncology.
Hong MK; Sapre N; Phal PM; Macintyre G; Chin X; Pedersen JS; Ryan A; Kerger M; Costello AJ; Corcoran NM; Hovens CM
Clin Exp Metastasis; 2014 Feb; 31(2):159-67. PubMed ID: 24085599
[TBL] [Abstract][Full Text] [Related]
4. Somatic mutations reveal complex metastatic seeding from multifocal primary prostate cancer.
Carm KT; Johannessen B; Bogaard M; Bakken AC; Maltau AV; Hoff AM; Axcrona U; Axcrona K; Lothe RA; Skotheim RI
Int J Cancer; 2023 Mar; 152(5):945-951. PubMed ID: 35880692
[TBL] [Abstract][Full Text] [Related]
5. Comparative Analysis of Genomic Alterations across Castration Sensitive and Castration Resistant Prostate Cancer via Circulating Tumor DNA Sequencing.
Fan L; Fei X; Zhu Y; Pan J; Sha J; Chi C; Gong Y; Du X; Zhou L; Dong B; Xue W
J Urol; 2021 Feb; 205(2):461-469. PubMed ID: 32897803
[TBL] [Abstract][Full Text] [Related]
6. Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer.
Fonseca NM; Van der Eecken K; Herberts C; Verbeke S; Ng SWS; Lumen N; Ritch E; Murtha AJ; Bernales CQ; Schönlau E; Moris L; Van Dorpe J; Annala M; Wyatt AW; Ost P
JCO Precis Oncol; 2022 Apr; 6():e2100543. PubMed ID: 35507889
[TBL] [Abstract][Full Text] [Related]
7. Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.
Pectasides E; Stachler MD; Derks S; Liu Y; Maron S; Islam M; Alpert L; Kwak H; Kindler H; Polite B; Sharma MR; Allen K; O'Day E; Lomnicki S; Maranto M; Kanteti R; Fitzpatrick C; Weber C; Setia N; Xiao SY; Hart J; Nagy RJ; Kim KM; Choi MG; Min BH; Nason KS; O'Keefe L; Watanabe M; Baba H; Lanman R; Agoston AT; Oh DJ; Dunford A; Thorner AR; Ducar MD; Wollison BM; Coleman HA; Ji Y; Posner MC; Roggin K; Turaga K; Chang P; Hogarth K; Siddiqui U; Gelrud A; Ha G; Freeman SS; Rhoades J; Reed S; Gydush G; Rotem D; Davison J; Imamura Y; Adalsteinsson V; Lee J; Bass AJ; Catenacci DV
Cancer Discov; 2018 Jan; 8(1):37-48. PubMed ID: 28978556
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.
Wei L; Wang J; Lampert E; Schlanger S; DePriest AD; Hu Q; Gomez EC; Murakam M; Glenn ST; Conroy J; Morrison C; Azabdaftari G; Mohler JL; Liu S; Heemers HV
Eur Urol; 2017 Feb; 71(2):183-192. PubMed ID: 27451135
[TBL] [Abstract][Full Text] [Related]
9. Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment.
Arnold RS; Fedewa SA; Goodman M; Osunkoya AO; Kissick HT; Morrissey C; True LD; Petros JA
Bone; 2015 Sep; 78():81-6. PubMed ID: 25952970
[TBL] [Abstract][Full Text] [Related]
10. Future directions for precision oncology in prostate cancer.
Mizuno K; Beltran H
Prostate; 2022 Aug; 82 Suppl 1(Suppl 1):S86-S96. PubMed ID: 35657153
[TBL] [Abstract][Full Text] [Related]
11. Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.
Sailer V; Schiffman MH; Kossai M; Cyrta J; Beg S; Sullivan B; Pua BB; Lee KS; Talenfeld AD; Nanus DM; Tagawa ST; Robinson BD; Rao RA; Pauli C; Bareja R; Beltran LS; Sigaras A; Eng KW; Elemento O; Sboner A; Rubin MA; Beltran H; Mosquera JM
Cancer; 2018 Mar; 124(5):1008-1015. PubMed ID: 29266381
[TBL] [Abstract][Full Text] [Related]
12. Transcriptome Wide Analysis of Magnetic Resonance Imaging-targeted Biopsy and Matching Surgical Specimens from High-risk Prostate Cancer Patients Treated with Radical Prostatectomy: The Target Must Be Hit.
Radtke JP; Takhar M; Bonekamp D; Kesch C; Erho N; du Plessis M; Buerki C; Ong K; Davicioni E; Hohenfellner M; Hadaschik BA
Eur Urol Focus; 2018 Jul; 4(4):540-546. PubMed ID: 28753844
[TBL] [Abstract][Full Text] [Related]
13. Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing.
Chen E; Cario CL; Leong L; Lopez K; Márquez CP; Li PS; Oropeza E; Tenggara I; Cowan J; Simko JP; Kageyama R; Wells DK; Chan JM; Friedlander T; Aggarwal R; Paris PL; Feng F; Carroll PR; Witte JS
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250416
[TBL] [Abstract][Full Text] [Related]
14. Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing.
Bjurlin MA; Carter HB; Schellhammer P; Cookson MS; Gomella LG; Troyer D; Wheeler TM; Schlossberg S; Penson DF; Taneja SS
J Urol; 2013 Jun; 189(6):2039-46. PubMed ID: 23485507
[TBL] [Abstract][Full Text] [Related]
15. Tracking the origin of metastatic prostate cancer.
Lindberg J; Kristiansen A; Wiklund P; Grönberg H; Egevad L
Eur Urol; 2015 May; 67(5):819-22. PubMed ID: 25246081
[TBL] [Abstract][Full Text] [Related]
16. Patterns of metastases of prostatic ductal adenocarcinoma.
Ranasinghe WKB; Brooks NA; Elsheshtawi MA; Davis JW; Bathala TK; Tang C; Troncoso P; Aparicio A; Tu SM; Pisters LL; Chapin BF
Cancer; 2020 Aug; 126(16):3667-3673. PubMed ID: 32453443
[TBL] [Abstract][Full Text] [Related]
17. Genomic Analysis of Localized High-Risk Prostate Cancer Circulating Tumor Cells at the Single-Cell Level.
Rangel-Pozzo A; Liu S; Wajnberg G; Wang X; Ouellette RJ; Hicks GG; Drachenberg D; Mai S
Cells; 2020 Aug; 9(8):. PubMed ID: 32784507
[TBL] [Abstract][Full Text] [Related]
18. Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review.
Van der Eecken K; Vanwelkenhuyzen J; Deek MP; Tran PT; Warner E; Wyatt AW; Kwan EM; Verbeke S; Van Dorpe J; Fonteyne V; Lumen N; De Laere B; Ost P
Eur Urol Oncol; 2021 Dec; 4(6):914-923. PubMed ID: 34801437
[TBL] [Abstract][Full Text] [Related]
19. Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time.
Hahn AW; Stenehjem D; Nussenzveig R; Carroll E; Bailey E; Batten J; Maughan BL; Agarwal N
Cancer Treat Res Commun; 2019; 19():100120. PubMed ID: 30743187
[TBL] [Abstract][Full Text] [Related]
20. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer.
Ranasinghe W; Chapin BF; Kim IY; Sooriakumaran P; Lawrentschuk N
BJU Int; 2020 Jun; 125(6):792-800. PubMed ID: 32176456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
